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ABSTRACT 
Metformin (Metf), the most commonly used type 2 diabetes drug, is known to affect the cellular 
housekeeping of copper. Recently we discovered that the structurally closely related 
propanediimidamide (PDI) shows a different cellular behaviour than metformin. Here we 
investigate the binding of these compounds to copper, to compare their binding strength. 
Furthermore we take a closer look at the electronic properties of these compounds and their 
copper complexes such as molecular orbital interactions and electrostatic potential surfaces. Our 
results clearly show that the copper binding energies cannot alone be the cause for the 
biochemical differentiation between Metf and PDI. We conclude that other factors such as pKa 
values and hydrophilicity of the compounds play a crucial role in their cellular activity. Metf in 
contrast to PDI can occur as an anion in aqueous medium at moderate pH, forming much 
stronger complexes particularly with CuII ions, suggesting that biguanides but not PDI may 
induce easy oxidation of CuI ions extracted from proteins. The higher hydrophobicity and lack of 
planarity of PDI may further differentiate it from biguanides in terms of their molecular 
recognition characteristics. These different properties could hold the key to metformin’s 
mitochondrial activity because they suggest that the drug could act at least in part as a pro-
oxidant of accessible protein-bound CuI ions. 
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INTRODUCTION 
It has been estimated that more than 300 million people suffer from the diabetes world-wide.1 
By 2030 the WHO estimates that diabetes will be the seventh highest cause of death.2 Type 2 
diabetes (T2D), which covers around 90% of all diabetes patients, is characterised by 
hyperglycaemia due to insulin resistance in peripheral tissues. One of the most effective and 
frequently administered antihyperglycemic T2D drugs is metformin (N,N-dimethylbiguanide, 
Metf; for its chemical structure see Figure 1), which is the first-line treatment because of better 
long-term outcomes compared with other therapies such as insulin secretagogues.3 It belongs to 
the biguanide family that also include other compounds with antihyperglycemic properties. Metf 
and other biguanide derivatives have been developed after it was discovered that the blood 
glucose-lowering ingredient in Goat’s Rue is guanidine and other guanidine derivatives such as 
galegine. Synthalin, a diguanide, was developed as a synthetic drug and was more potent and 
showed lower toxicity. However, the liver damage caused by both guanidine and diguanides, 
were a stimulant to search for safer alternatives which led to the development of biguanides as 
T2D drugs.3 
The exact molecular mechanism of Metf and other T2D drugs remains unclear. One suggested 
mechanism of action is suppression of mitochondrial respiration by inhibition of complex I4, 5, 
however, the precise mechanism of this inhibition has not yet been established.  
Dysfunctional copper metabolism is implicated in the development of several diseases. 6-9 
Mutations in the gene ATP7A results in copper deficiency in most organs, which is the cause of 
Menkes's disease10, 11 and copper overload resulting from ATP7B mutation is the cause of 
Wilson's disease.12 Dysregulation of copper is also suspected in other diseases, particularly those 
involving protein misfolding13-15 and in diabetes.16-20  
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In our previous study we demonstrated for the first time that the metal-binding properties of 
Metf, particularly towards copper, may be one factor in cell responses to this drug.21 Metf and 
biguanide (BG) show antihyperglycemic properties and no free mitochondrial CuII could be 
detected by a CuII specific fluorescence probe. In contrast propanediimidamide (PDI) showed no 
antihyperglycemic effect and free CuII was detected. BG and Metf regulate AMP-activated 
protein kinase (AMPK), whereas PDI does not have such an effect. Regulation of S6 
phosphorylation is observed for all three compounds. Interestingly, Metf does not lower the 
urinal copper concentration which in T2D patients is raised, whereas triethylenetetramine (trien) 
decreases the urinal copper concentration, but has no antihyperglycemic effect.  
 
FIGURE 1 
 
However, it remained unclear whether Metf binds to CuI or CuII. In water CuII is the more 
stable oxidation state. In living organisms a complex machinery of cupric reductase, a CuI 
specific membrane transport protein, and chaperone proteins within the cells exist which 
effectively does not allow free copper ions at cellular level.22-29 The chaperone proteins play a 
vital role in the copper transport system and are not only abundant in the cell but also in the 
mitochondria. CuI is bound to the chaperones by two cysteinates. At the unbound state these 
cysteines are protonated, therefore, a perfectly designed proton array consisting of other amino 
acids is constructed to deprotonate the receiving chaperones or enzymes while simultaneously 
protonating the transporter protein to lower its copper binding affinity. Moreover, copper 
metalloenzymes, where the unique copper redox chemistry is needed, are able to bind both CuI 
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and CuII. Therefore, there are various possibilities of drug interaction with CuI/II proteins and 
Metf could potentially interact with protein bound CuI/II ions. 
There are major differences in the coordination chemistry of CuI and CuII. At the lower 
oxidation state CuI prefers binding to soft ligands such as thiols, thiolates (cysteine) or thioethers 
(methionine) or sp2 containing nitrogen (histidine). On the other hand, CuII favours binding to 
slightly harder ligands such as amines and imines. According to Pearson’s hard and soft acids 
and bases (HSAB) concept CuI is classified as a soft acid whereas CuII is classified as an 
intermediate acid.30-33 Also CuI has 2-4 ligand atoms in the first coordination sphere compared to 
3-6 for CuII. Generally a tetrahedral coordination sphere is observed for CuI, whereas a square 
planar ligand orientation is commonly found for CuII.34,35 In an enzymatic environment a mixed 
coordination sphere of sulphur and nitrogen containing ligands assist to stabilise CuI and at the 
same time facilitates the reversible redox chemistry of CuI/II. 
Similar to the imidazole residue in histidine a sp2 hybridised N1 (for atom labels see Figure 2) 
is the ligand atom for BG, Metf and PDI. This means that π-backbonding can occur and stabilize 
the lower CuI oxidation state by transferring electron density into the π-orbitals of the ligands, 
see Figure 3. This type of molecular orbital (MO) interaction may also be important for CuII as 
its 3d-orbitals are almost filled up. The methylene CH2 moiety in PDI compared to the secondary 
amine N2 in BG and Metf causes a disruption of the π-system, whereas the lone-pair of N2 can 
contribute electron density into the adjacent carbon pz-orbital in BG and Metf, which results in a 
planar molecular structure for the latter ones and a non planar geometry for PDI in the complex. 
This is similar to the stabilisation effect detected in peptide bonds. 
 
FIGURE 2 
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FIGURE 3 
 
Additionally, the N2-H group contains a protic hydrogen whereas the methylene hydrogens 
cannot undergo proton exchange in aqueous media. Deprotonated metal complexes of PDI are 
known, however, those are synthesised in non-protic solvents under conditions that avoid any 
water contamination.36-38 Due to the protic hydrogen the most stable neutral form of BG and Metf 
in water is a tautomer in which the N2-H proton is formally transferred to N1 or N3.39 This leads 
to a fully conjugated π-system in the ligands. However, only the N2 can then act as a donor atom 
as has been observed with a similar ligand in a known AgI complex.40 
Biguanides formally belong to the 1,3,5-triazapentadienyl41, 42 (also known as imidoylamidine) 
ligand family and PDI is a member of the 1,5-diazapentadienyl35, 38, 43 (also known as β-
diketiminate) ligand class which are well established as metal ion ligands in inorganic 
coordination chemistry. However, their structure and chemistry is mainly established in 
nonaqueous solvents, hence, their properties cannot be transferred directly to aqueous 
environments particularly biosystems with very sensitive pH range. 
The protonation equilibria of BG have been studied along with complex formation with CuII at 
a pH range of 2-12.44, 45 Firstly, BG predominately exists in an equilibrium between its 
monoprotonated and neutral form at physiological pH and no deprotonated BG-H was reported 
for the given pH range. Secondly, the formation of [CuII(OH)(BG)]+ was observed to be the 
major Cu-BG complex, however, binary CuII-BG complexes such as [Cu(BG)2]2+, [Cu(BG)(BG-
H)]+ and [Cu(BG-H)2]0 were also observed at slightly higher pH values. The pKa value of 6.88 
was reported for [Cu(OH)(BG)]+ hence indicating the possibility of deprotonated BG while being 
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coordinated to CuII. Neither Metf nor PDI have been studied in this detail. However, these results 
are at least qualitatively transferable to Metf. 
In a recent study the antimicrobial properties of binary metformin metal complexes were 
studied.46,47 Among other physico-chemical properties the cyclic voltammogram of 
[CuII(Metf)2]2+ was measured against a Ag/AgCl electrode and showed a reduction peak at 
320mV and oxidation peak at 490mV giving a E1/2 of +405 mV which is in the range of the 
reduction potentials of copper containing enzymes.48 
Here we aim to build upon our previous work on the cellular response to T2D drugs and in 
particular on the observed variations of free copper levels after drug treatment. We gain deeper 
insight into the copper binding properties of BG and Metf with focus on possible differences to 
PDI, which may be important for their different biological antihyperglycemic properties. We 
compute binding energies and compare the optimized structures to known crystal structures, in 
the process benchmarking the computational methodology for such systems.  Furthermore we 
will investigate the electronic properties such as molecular orbitals and electrostatic potentials of 
these molecules. 
 
MATERIALS AND METHODS 
Computational Details 
Geometries of all the computed structures were obtained by optimization with B3LYP49-53. The 
basis set Def2-TZVPD54 was used for all atoms. For Cu(I) complexes singlet spin-multiplicity 
was used, while for Cu(II) doublet spin-multiplicity was used.  For the open-shell species spin-
contamination was found to be negligible. Each structure was verified to be a minimum by the 
absence of imaginary frequencies in the vibrational analysis. The calculations were performed 
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using Gaussian 09 A.02 and C.0155. We also tested other DFT functionals including BP8651, 56, 
M0657 and M06L58 which showed no significant difference to B3LYP. Natural bond 
orbital (NBO) charges were calculated with the integrated NBO 3.159 within Gaussian 09. 
 
RESULTS 
A. Comparision of X-ray Structures and Computed Complexes 
Several crystal structures are known for bisbiguanide-copper complexes. Three describe the 
[Cu(BG)2]2+ complex and contain different counterions.60-62 Although these complexes are planar 
they are not symmetric in terms of their bond lengths. An average over all three structures is 
presented in Table 1 and will be discussed here in comparison to the DFT optimized structure. 
One structure for the neutral complex Cu(BG-H)263 has been published which contains the 
deprotonated biguanide (BG-H). The deprotonation was confirmed by visual inspection of H-
bond contacts to the deprotonated N2(-). 
The observed Cu-N1 bond length 1.944 Å is in the normal range of CuII-N ligand bonds. The 
computed Cu-N bond distance 1.980 Å is slightly longer, however, this is expected and is a 
known effect when computing complexes in gas phase and comparing them to crystal structures. 
Also the Cu-N bond length in the different crystal structures can vary from 1.921 Å to 1.958 Å 
for complexes with the neutral BG ligand. The most symmetrical, coplanar X-ray structure 
COBMAH61 is Ci symmetric with Cu-N distances of 1.933 and 1.939 Å. This feature is 
reproduced by the DFT calculation with slightly different Cu-N bonds of 1.978 and 1.982 Å. 
Interestingly, the computed minimum structure is slightly twisted and has C2 symmetry with 
regards to the heavy atoms which is abolished by the non-planar H-atoms of the amine groups. 
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The coplanar, D2h symmetrical geometry is in fact computed to be a rotational transition state in 
the gas phase with a negligible barrier of ΔE‡ 1.04 and ΔG‡ 3.65 kcal/mol.  
The observed N1-C1 bond length (X-rayav: 1.292 Å; DFT: 1.299 Å) is slightly longer than a 
pure C-N double bond and whereas the C1-N2 (X-rayav: 1.373 Å; DFT: 1.383 Å) and C1-N3 (X-
rayav: 1.343 Å; DFT: 1.344 Å) are much shorter than a C-N single bond, which indicates 
conjugation of the N2-lone pairs into the N1-C1 double bound. The computed N-C bonds are in 
much better agreement with the crystal structure compared to the metal-ligand bond because 
these bonds are less affected by crystal packing. Particularly the changes upon deprotonation of 
the secondary amine N2-H in the N1-C1 and C1-N2 bonds which indicate a delocalization of the 
negative charge within the ligand bonds that form the metallacycle is very well reproduced in the 
computed structure. The observed differences between the different X-ray structures are possibly 
explained by the different counter ions. Remarkably, an almost negligible shortening of -0.002 Å 
for the Cu-N bond length is observed for the neutral complex Cu(BG-H)263 compared to the 
average of the cationic complexes, whereas the DFT calculations reveal a stronger reduction of -
0.009 Å indicating a much larger increase in the Cu-N bond strength than the experimental 
results are suggesting.  
 
TABLE 1 
 
Moving on to the Metf-Cu complexes, in total five crystal structures are known, see Table 2, 
three include the neutral Metf47, 64, 65 and two the deprotonated metformin (Metf-H)64, 65 with CuII. 
Some differences compared to the BG-Cu complexes in the bond distances can be observed 
which are due to the methyl groups that abolish the symmetry of the BG complex. The N1-C1 
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bond becomes slightly longer (X-rayav: 1.305 Å; DFT: 1.307 Å) and the N1’-C1’ slightly shorter 
(X-rayav: 1.276 Å; DFT: 1.298 Å) compared to the N1-C1 bond (X-rayav: 1.291 Å; DFT: 
1.299 Å) in the BG complex. This alteration is also observed in the computed complex, although 
the decrease in the N1’-C1’ bond is only marginal. The asymmetrical nature of the ligand is also 
noticeable in different Cu-N bond distances of Cu-N1 1.942 Å and Cu-N1' 1.929 Å, surprisingly 
the DFT computed Cu-N bond distances show an opposite trend with 1.973 Å and 1.980 Å, 
which might be due to crystal packing effects compared to the gas-phase computed, single-
molecule structure. However, the other bond distances are in excellent agreement.  
The two crystal structures CuII(Metf-H)2·H2O (ETOFOI)65 and Cu(Metf-H)2·8H2O (EFIXUM)64 
were synthesized under basic conditions. The ETOFOI structure complex contains two 
CuII(Metf-H)2 molecules in the unit cell with ETOFOI-A resembling the CuII(BG-H)2 more 
closely than ETOFOI-B and EFIXUM. The best agreement with the DFT optimized Cu(Metf-H)2 
structure is also with ETOFOI-A. The lengthened N1-C1 and N1’-C1’ double bond is 
particularly well reproduced by the B3LYP optimized structure.  
Surprisingly, in EFIXUM and ETOFOI-B hardly any increase in the N1-C1 bond and decrease 
in the C1-N2 bond is observed, which most likely is due to strong H-bonding of crystal water in 
the proximity of N2. Two crystal waters are close two N2(-) in EFIXUM at a distance of 2.86 Å 
and 2.91 Å (N2-O distance), whereas one water is found in ETOFOI-B to be 2.84 Å away from 
N2(-). 
Overall, the crystal structures of the neutral complex CuII(Metf-H)2 indicate the possibility of 
the formation of stable CuII complex with deprotonated metformin at basic conditions. 
 
TABLE 2 
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Only one crystal structure for the homoleptic PDI complex is known.66 The Cu-N bond 1.956 
Å in the [CuII(PDI)2]2+ complex is slightly longer than in the BG complex 1.943 Å, which is also 
observed in the computed structure with 1.999 Å compared to 1.980 Å, for PDI and BG 
respectively. In contrast to the BG complexes the C1-C2 bond (1.501 Å) in the PDI complex is 
much longer compared to the C1-N2 bond (1.373 Å) in [CuII(BG)2]2+ and closer to a pure single 
C-C bond than a double bond.  
Intrigued by this long C1-C2 bond we calculated the rotational barrier of the free, neutral 
ligand of 2.42 kcal/mol for PDI and 18.20 kcal/mol for BG. The much higher rotational barrier 
for BG gives an indication about the strength of the conjugation of the N2 lone pair into the 
adjacent N1-C1 double bond. 
 
TABLE 3 
 
B. Binding Energies of CuI/II Complexes 
The binding energies that are presented in Table 2 were computed in two different ways. The 
interaction energy ΔEint corresponds to the binding energy of the Cu-centre or CuOH fragment 
with the ligand in its geometry found in the optimized complex structure. On the other hand, the 
binding free energy ΔG is determined using the lowest energy tautomer and conformer of the 
ligands. The negative ΔG is equal to the dissociation energy De. The difference between the 
energy of the ligand in its complex geometry and its lowest tautomer and conformer is called 
preparation energy ΔEprep. 
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We have computed binding energies for CuI and CuII complexes of the mono-L complexes, the 
homoleptic, bis-L complexes and the mixed [CuI/II(OH)(L)]0/+ complexes. The latter is particular 
important in aqueous media as this is the major CuII-BG species at physiological pH in most 
biological compartments. We also calculated the complexes with deprotonated ligands as this 
might become important at higher physiological pH, occurring for example inside the 
mitochondria. 
 
TABLE 4 
 
Firstly, the [CuI/II(L)]+/2+ complexes are discussed. Among all ligands Metf shows the strongest 
interaction energy with CuI, however, due to lower ΔEprep PDI forms the strongest [CuI(L)]+ 
complex. Interestingly, for BG and PDI ΔEint is almost equal. En binds around 25-30 kcal/mol 
weaker to CuI compared to the other ligands, but De is only 6-16 kcal weaker, which as well is 
due to a small preparation energy. The weaker binding of en is due to the lack of π-backbonding, 
and also larger steric strain as en forms a 5-membered metallacycle compared to the 6-membered 
metallacycle of the BG, Metf and PDI-Cu complexes. 
 
FIGURE 4 
 
The CuII complexes for BG, Metf and PDI are more than 200 kcal/mol more stable than the CuI 
complex which is due to stronger Coulomb and orbital interactions. Whereas the en complex 
does not receive as strong a stabilisation compared to the other ligands. This could be due to two 
factors, the σ-bonding with the N lone pair is smaller in the sp3 hybrid N compared to the slightly 
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larger sp2 hybid lone pair with more s-character. The other factor, although this plays a minor 
role, is the possibility of the occupied ligand π-orbitals donating electron density towards the Cu-
d9 center. Overall, Metf binds strongest, however, the De of PDI is only 3.4 kcal/mol lower. 
Secondly, we will consider the homoleptic [CuI/II(L)2]+/2+ complexes. For BG, Metf and PDI 
complexes we observe similar trends as in the mono-complexes, with an even stronger 
stabilisation for PDI compared to BG and Metf due to a much larger ΔEprep for the latter ones. We 
also include trien in this group of complexes. Obviously due to its tetradentate, chelating 
properties it surpasses BG, Metf and PDI at equal molarity, however, we are more interested in 
its binding properties in comparison to copper-ligand complexes with a saturated copper ligand 
sphere. Trien has almost the same ΔEint than en, but a larger De due to entropic effects by 5 
kcal/mol with CuI and by ~10 kcal/mol with CuII which agrees with the experimentally observed 
stronger stabilisation of trien with CuII. 
Next we will investigate the binding of BG, Metf, PDI and en in a mixed complex with 
Cu(OH), where OH is a stronger ligand than the neutral, bidentate ligands. The CuI cation  forms 
a strong bond with the hydroxide anion, which results in weak binding of a second, non-anionic 
ligand. Here we observe a surprising order for the CuI complexes, PDI forms the strongest mixed 
complexes, en follows as the second strongest, then BG and Metf forms the weakest complex. 
The differences between the ligands is again mainly due to the larger ΔEprep for BG and Metf 
compared to low ΔEprep for PDI and en. 
The mixed CuII(OH)(L) complexes are slightly stronger than the CuI(L) complexes, with very 
similar trends and similar stabilities for BG, Metf and PDI. 
In addition to the complexes with neutral ligands we have also calculated the binding energies 
for the deprotonated BG-H, Metf-H and PDI-H. It is important to point out here that at higher pH 
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BG and Metf can be deprotonated in aqueous medium, whereas PDI, even when in a metal 
complex which lowers its pKa, will only be deprotonated above pH 14 in non-aqueous medium 
as the methylene group in PDI cannot be deprotonated by bases in aqueous media. 
These anionic ligands bind much stronger than the neutral counterparts as they have much 
larger ionic bonding contributions than the neutral ligands. Also the CuII complexes receive an 
even stronger stabilization than the CuI complexes. This could indicate an easier oxidation 
compared to the neutral ligands when a CuI ion is extracted from a protein by Metf-H. In 
addition, these deprotonated forms of the biguanides alone might be a strong enough ligand to 
extract CuI from proteins with thiolate ligands. This modelling indicates that any copper-
dependent effects of the drug may be restricted to or most prominent in the mitochondria and 
other compartments in the body where physiological pH is above the typical range, allowing 
deprotonation of the drug. Such pH-dependent activation or priming could potentially explain 
why metformin is almost invariably found in the biological literature to act on the mitochondria, 
with very few effects reported in other cellular compartments.  
 
C. Electronic Properties 
To gain a deeper understanding about the biguanide type ligands compared to the PDI we take 
a look at the molecular orbitals (MO) of these ligands in their geometry in a complex, see Figure 
4. For simplicity we will concentrate on the π-orbitals and the MOs with the N1 lone pairs.  
The lowest lying MOs with π-character in BG and PDI are the MO-19. PDI, which is not 
planar, still shows a π-like plane with one σ-C2-H bond above and the other σ-C2-H bond 
mixing with the N1-C1 double bond plus contribution from the N3 lone pairs. The MO-19 in BG 
is a mix of π and σ character. The lone pairs of N2 and N3 are mixing with the pz AO of the sp2 
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hybridized C1, plus σ-character from the N1-H bond. For BG the MO-21 looks very similar to 
the MO-19 with σ- and π-character, except that it is the negative combination of the AOs and 
therefore higher in energy. The MO-21 in PDI only shows σ-character, which explains the much 
lower rotational barrier for PDI compared to BG. The MO-22 is basically the same for both 
molecules. MO-23 in BG is a pure combination of N2 and N3 lone pairs, whereas in PDI as there 
is no lone pair on C2 this MO is a mix of π-MO with contributions from the N1-C1 double bonds 
and the N3 lone pairs plus out-of plane C2-H σ-bond character. MO-24 is the positive 
combination of the N1 lone pairs which is responsible for bonding to the empty 4s AO of Cu. 
The next two MOs 25 and 26 are identical for BG and PDI and are pure π-MOs. The HOMO, 
MO-27, is the negative combination of the N1 lone pairs and donate electron density into the 
empty 4p AO of Cu. These MOs show that the electron density on N1 is very similar in BG and 
PDI which explains the strong similarities in the observed binding energies for these ligands with 
Cu. 
To emphasise this point we calculated the NBO charges for the [Cu(L)]2+ complexes, Table 3. 
The charge on Cu decreases from +1.87, +1.84 to +1.80 for BG, PDI and en, respectively. This is 
coincident with decreasing negative charge on the ligand nitrogens N1 of these ligands from -
0.87, -0.84 to -0.80.  Figure 2 illustrates the possible orbital interactions for the sp2-type N in BG, 
Metf and PDI compared to the sp3-type N in en and trien. The former ones are capable of 
stronger bonds due to σ-donation while at the same time receiving electron density from the 
metal centre via π-backdonation, these two types of bonding have a synergistic effect and 
reinforce each other. On the other hand the pure σ-donor ligands en and trien cannot accept 
electron density in π-MOs, which results in weaker binding. The small difference between BG 
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and PDI can either be due to slightly larger σ-donation or smaller π-backdonation in PDI or a 
combination of both. 
 
TABLE 5 
 
D. ESP Maps 
The electrostatic potential (ESP) maps for BG and PDI in their neutral forms are presented in 
Figure 5. Interestingly, the PDI-A shows a slightly more negative potential around the N1 atoms 
which will form coordination bonds toward Cu. This means that PDI is a slightly stronger Lewis 
base than BG-A and is consistent with our findings that the PDI has a larger ΔEint. It has to be 
pointed out here that the presented structure PDI-A is not a minimum structure and therefore not 
stable in nature; however, this is the conformation that will bind to a metal center in a bidentate 
binding mode. BG-A on the other hand is a minimum structure, which also is in one sense 
surprising as the two N1 lone pairs should strongly repel each other, however, it seems that the 
p-stabilisation as shown by the MOs exceeds the steric repulsion. Also the methylene moiety 
causes a greater part of PDI-A to be hydrophobic compared to BG-A, which could be important 
in terms of molecular recognition when binding to a Cu centre of a protein. Therefore, not only 
does PDI cause greater steric hindrance due to its lack of planarity but also introduces repulsive 
or at least weaker interactions with H-bond acceptors. 
 
FIGURE 5 
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The PDI-B represents the lowest energy conformer of the neutral PDI. An internal H-bond in 
PDI-B results in a very weak hydrophilicity, with strong, large areas that can be described as 
lipophilic. In contrast the BG-B, which is not the lowest tautomer of BG, shows much more 
pronounced negative and positive moieties which results in stronger H-bond donor and acceptor 
properties than PDI-B. This is suggestive evidence that PDI may be able to penetrate cell 
membranes, whereas BG and Metf need to be taken up via transmembrane transporters. 
The lowest energy conformer and tautomer of BG-C does not show as strong Lewis acid or 
basic sites compared to BG-B, however, there are also fewer hydrophobic areas above the 
molecules plane which means that solvation and stabilisation due to H-bonding can be stronger 
not only on the edges of the molecules but also along the molecular plane. 
 
 
DISCUSSION 
In the presented study we find that the biologically observed differences between neutral 
biguanide compounds (BG and Metf) and PDI cannot be explained by different Cu-binding 
energies. These ligands are electronically too similar and the substitution of the secondary amine 
to methylene has no negative effect on the complex formation via the N1 nitrogens for PDI. 
However, the secondary amine of biguanides can be deprotonated in aqueous medium as the pKa 
value is reduced when BG or Metf are coordinated to CuI/II. These anions form much stronger 
complexes compared to their neutral form. It is known that the mitochondrial matrix pH is higher 
than normal cellular or serum pH. Inside the mitochondria it is possible that the equilibrium is 
shifted towards the CuI/II(Metf-H) complex. Extraction of CuI ions from proteins is possible and 
subsequent oxidation to CuII would remove the redox active CuI ions from the mitochondria. This 
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suggests that metformin could act in cells at least in part as a copper-binding prodrug, becoming 
activated by elevated mitochondrial pH. This is consistent with the strong emphasis on 
mitochondrial effects of this drug in the biological literature. In addition, this explains the 
differences between mitochondrial responses to metformin and PDI, as the latter agent only 
becomes deprotonated at much higher pH. There is a possibility that high binding affinities of 
Metf-H to copper could significantly affect the mitochondrial copper pool, which would 
probably have an impact on metal homeostasis of other metals and lead to mis-metallation of 
important metalloproteins.67 Redox properties of such copper complexes may interfere with the 
sensitive redox chemistries occurring inside the cell, such as the mitochondrial electron transport 
chain.  
Furthermore, ESP maps show that molecular recognition processes, which are copper-
independent, could play a vital role in explaining the different drug properties of biguanides and 
PDI. Further work will establish if the much stronger hydrophilicity of BG facilitates its 
mitochondrial activity. On the other hand, we showed higher lipophilicity of PDI, which might 
enable it to penetrate cell membranes without relying on membrane transport proteins. 
In summary, these calculations clearly demonstrate that metformin is a pH-sensitive copper-
binding agent with a pKa within the physiological pH range and a strongly hydrophilic character. 
Together, these properties of metformin distinguish it from the other copper-binding agents we 
have studied and they are also likely to account for many of the biological/therapeutic responses 
to the drug. 
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FIGURES 
 
 
 
Figure 1. Compounds used as ligands 
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Figure 2. Numbering of atoms in X-ray and computed structures. 
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Figure 3. Schematic representation of possible orbital interactions Cu complexes with BG, Metf 
and PDI (A) and with en and trien (B) 
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Figure 4. Molecular orbitals for BG and PDI 
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Figure 5. Electrostatic potential maps for BG and PDI. Red negative, green neutral and blue 
positive ESP values. 
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TABLES.  
 
Table 1. Comparison of critical bonds† (distance in Ångström) of [CuII(BG)2]X1,2 (X= CO32¯, Cl¯, 
[CuII(C5H7O2)(Cl)]¯) and CuII(BG-H)2 crystal structures and computed [CuII(BG/BG-H)2]2+/0 
complexes. 
BG CSD code X Cu-N N1-C1 C1-N2 C1-N3 
X-ray BGCUCB60  CO32 ¯ 1.951 1.296 1.374 1.351 
 COBMAH61 [CuII(C5H7O2)(Cl)] ¯ 1.936 1.287 1.372 1.337 
 ZZZDZQ0162 Cl ¯ 1.941 1.289 1.373 1.342 
 Ø‡([Cu(BG)2]2+  1.944 1.292 1.373 1.344 
 STD  0.011 0.009 0.009 0.012 
 MUE  0.023 0.016 0.017 0.018 
B3LYP [Cu(BG)2]2+  1.980 1.299 1.383 1.344 
X-ray SAPFUL63  — 1.941 1.320 1.355 1.360 
B3LYP Cu(BG-H)2  1.971 1.318 1.337 1.383 
 
†Experimental bond lengths are averaged for each crystal structure (BGCUCB C1-
symmetry, COBMAH Ci symmetry and ZZZDZQ01 C1 symmetry. ‡Average of all 
[CuII(BG)2]X1,2 structures. 
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Table 2. Comparison of critical bond† (distance in Ångström) of [CuII(Metf)2]X1,2 (X= ClO4¯, CO32¯, Cl¯)  
and CuII(Metf-H)2 crystal structures and computed complexes. 
Metf CSD code X Cu-N1 Cu-N1' N1-C1 N1'-C1' C1-N2 C1'-N2 C1-N3 C1'-N3' 
X-ray AJUHUJ47 ClO4¯ 1.944 1.944 1.303 1.268 1.374 1.384 1.354 1.344 
 HIBPOX68 CO32 ¯ 1.931 1.920 1.305 1.282 1.364 1.393 1.342 1.322 
 HIHDUX69 Cl ¯ 1.948 1.931 1.307 1.279 1.377 1.379 1.342 1.344 
 Ø([Cu(Metf)2]2+)  1.941 1.932 1.305 1.276 1.372 1.385 1.346 1.337 
 STD  0.009 0.012 0.002 0.007 0.007 0.007 0.007 0.013 
 MUE  0.010 0.012 0.002 0.008 0.008 0.008 0.008 0.015 
B3LYP [Cu(Metf)2]2+  1.973 1.980 1.307 1.298 1.389 1.379 1.346 1.348 
X-ray EFIXUM64 — 1.943 1.921 1.312 1.306 1.372 1.350 1.365 1.386 
 ETOFOI65-A† — 1.938 1.928 1.324 1.320 1.358 1.350 1.368 1.371 
 ETOFOI65-B† —! 1.950! 1.923! 1.315! 1.310! 1.371! 1.342! 1.357! 1.391!
 Ø(Cu(Metf-H)2)  1.944 1.924 1.317 1.312 1.367 1.347 1.363 1.383 
 STD  0.006 0.004 0.006 0.007 0.008 0.005 0.006 0.010 
 MUE  0.006 0.004 0.007 0.008 0.009 0.005 0.006 0.012 
B3LYP Cu(Metf-H)2  1.970 1.967 1.323 1.320 1.343 1.332 1.383 1.388 
 
†The unit cell of ETOFOI contains two Cu(Metf-H)2 molecules. 
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Table 3. Comparison of critical structural parameters (bond distance in Ångström, angle 
in degrees) of [CuII(PDI)2][ClO4]2 crystal structures and computed [CuII(PDI/PDI-
H)2]2+/0 complexes. 
PDI CSD code X Cu-N N1-C1 C1-C2 C1-N3 ∠N1-N2-C3-C2† 
X-ray MALDOU66  ClO4¯ 1.956 1.288 1.501 1.332 21.6 
B3LYP [Cu(PDI)2]2+  1.999 1.297 1.514 1.336 22.1 
 [Cu(PDI-H)2]0  1.976 1.321 1.403 1.394 1.4 
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Table 4. Binding energies of Cu complexes. B3LYP/Def2-TZVPD. Energies in kcal/mol. 
   BG Metf PDI en trien 
 [CuI(L)]+ ΔEint -119.77 -125.07 -120.74 -95.15  
  ΔG (=-De) -84.71 -87.45 -94.18 -78.60  
 [CuII(L)]2+ ΔEint -331.77 -347.81 -332.66 -270.92  
  ΔG (=-De) -286.23 -299.91 -296.49 -250.70  
        
 [CuI(L)2]+ ΔEint -183.80 -187.80 -186.28 -154.32 -151.04 
  ΔG (=-De) -105.97 -106.64 -124.85 -112.52 -117.58 
 [CuII(L)2]2+ ΔEint -489.52 -505.09 -488.51 -410.06 -409.90 
  ΔG (=-De) -391.59 -402.19 -405.96 -355.32 -364.10 
        
 [CuI(OH)(L)] ΔEint -50.88 -47.80 -51.05 -42.10  
  ΔG (=-De) -16.26 -12.02 -34.12 -24.60  
 [CuII(OH)(L)]+ ΔEint -138.25 -144.61 -138.73 -112.33  
  ΔG (=-De) -97.37 -101.23 -105.93 -88.99  
        
 [CuI(L-H)] ΔEint -229.86 -231.38 -234.86   
  ΔG (=-De) -200.71 -201.60 -203.80   
 [CuII(L-H)] + ΔEint -555.26 -561.38 -566.70   
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  ΔG (=-De) -511.20 -518.40 -530.24   
        
 [CuI(L-H)2]¯ ΔEint -353.80 -351.71 -359.31   
  ΔG (=-De) -220.55 -220.70 -218.21   
 [CuII(L-H)2] ΔEint -836.32 -837.06 -846.10   
  ΔG (=-De) -678.65 -680.45 -680.12   
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Table 5. NBO charges for [CuII(L)]2+, L=BG, PDI and en. 
 BG PDI EN   
CuII +1.38 +1.34'+1.30'  
N1 )0.87' )0.84' )0.80'  
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For TOC graphic: 
 
 
